Moderate EvidencePromising research with growing clinical support from multiple studies
Alternatives for Premenstrual Syndrome (PMS)
Premenstrual syndrome (PMS) refers to a recurring pattern of physical, emotional, and behavioral symptoms that arise in the luteal phase (the days after ovulation and before menstruation) and improve shortly after bleeding begins. Common symptoms include bloating, breast tenderness, headaches, cravings, fatigue, irritability, anxiety, low mood, sleep changes, and difficulty concentrating. When mood symptoms are severe, impair daily function, and follow a strict cyclical pattern, the diagnosis may be premenstrual dysphoric disorder (PMDD), a DSM‑5 condition related to, but more intense than, PMS. PMS affects up to 75% of menstruating individuals to some degree, while clinically significant PMS is estimated at 20–30%, and PMDD around 3–8%. Comparing Western and Eastern approaches helps people understand both evidence-based treatments and personalized, tradition-informed strategies.
Western medicine classifies PMS and PMDD using symptom diaries (e.g., the Daily Record of Severity of Problems) tracked across at least two cycles to confirm timing and functional impact. Treatment spans lifestyle measures (exercise, sleep, stress management), psychological strategies (cognitive behavioral therapy), targeted supplements (calcium has the most consistent data; magnesium, vitamin D, and vitamin B6 show mixed evidence), and medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) may help cramps and breast pain. Selective serotonin reuptake inhibitors (SSRIs) are among the best-studied options for severe symptoms and PMDD; they may be taken daily or only in the luteal phase. Combined hormonal contraceptives, particularly drospirenone-containing 24/4 regimens, can reduce symptoms by suppressing ovulation and stabilizing hormonal fluctuations. A commonly used botanical in the West, chaste tree (Vitex agnus-castus), has supportive but heterogeneous evidence and is generally well tolerated. Each option has potential side effects and specific considerations—SSRI-related nausea or
womens-health
Updated March 16, 2026